The Challenges of Cardiac Resynchronisation Therapy in Left Ventricular Assist Device Supported Patients

Heart failure (HF) affects approximately 2% of the adult population worldwide resulting in poor quality of life with increased mortality [1]. Cardiac resynchronisation therapy (CRT) is a standard device therapeutic option in symptomatic HF patients with reduced ejection fraction and electrical dyssynchrony [2]. However, the long-term prognosis of HF remains poor with 1-year mortality of 20 –25% despite the optimal therapies [1]. In such refractory cases, continuous-flow left ventricular assist device (CF-LVAD) implantation is becoming the standard of care [3].

Source: Heart, Lung and Circulation - July 10, 2020 Category: Cardiology Authors: Nirav Patel, Joseph Radojevic Tags: Editorial Source Type: research